ES2531109T3 - Compuestos de imidazopiridinil-aminopiridina - Google Patents

Compuestos de imidazopiridinil-aminopiridina Download PDF

Info

Publication number
ES2531109T3
ES2531109T3 ES10841702T ES10841702T ES2531109T3 ES 2531109 T3 ES2531109 T3 ES 2531109T3 ES 10841702 T ES10841702 T ES 10841702T ES 10841702 T ES10841702 T ES 10841702T ES 2531109 T3 ES2531109 T3 ES 2531109T3
Authority
ES
Spain
Prior art keywords
unsubstituted
substituted
heteroatoms selected
membered rings
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10841702T
Other languages
English (en)
Inventor
Mark A Ashwell
Chris Brassard
Anton Filikov
Jason Hill
Steffi Koerner
Jean-Marc Lapierre
Yanbin Liu
Nivedita Namdev
Robert Nicewonger
Rocio Palma
Manish Tandon
David Vensel
Akihisa Matsuda
Shin Iimura
Yuko Yamamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arqule Inc
Original Assignee
Arqule Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule Inc filed Critical Arqule Inc
Application granted granted Critical
Publication of ES2531109T3 publication Critical patent/ES2531109T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)

Abstract

Un compuesto que tiene la Fórmula I:**Fórmula** o una de sus sales o ésteres farmacéuticamente aceptables, en la que: X1 es N y X2 es CRx; cada uno de Rx, R1 y R3 es independientemente H, hidroxilo, halógeno, ciano, nitro, alquilo C1-C6 no sustituido o sustituido, alcoxi C1-C6 no sustituido o sustituido, amino no sustituido o sustituido, arilo C6-C10 sin sustituir o sustituido, heteroarilo no sustituido o sustituido que comprende uno o dos anillos de 5 o 6 miembros y 1-4 heteroátomos seleccionados entre N, O y S, carbociclo C3-C10 no sustituido o sustituido, o heterociclo no sustituido o sustituido que comprende uno o dos anillos de 5 o 6 miembros y 1-4 heteroátomos seleccionados entre N, O y S; x es 0, 1, 2 o 3; y es 0, 1, 2, 3 o 4; cada Rp1 es independientemente hidroxilo, halógeno, nitro, ciano, alquilo C1-C6 no sustituido o sustituido, alcoxi C1-C6 no sustituido o sustituido, o amino sin sustituir o sustituido; cada Rp2 es independientemente hidroxilo, halógeno, nitro, ciano, alquilo C1-C6 no sustituido o sustituido, alcoxi C1-C6 no sustituido o sustituido, amino no sustituido o sustituido, arilo C6-C10 sin sustituir o sustituido, heteroarilo no sustituido o sustituido que comprende uno o dos anillos de 5 o 6 miembros y 1-4 heteroátomos seleccionados entre N, O y S, carbociclo C3-C10 no sustituido o sustituido, o heterociclo no sustituido o sustituido que comprende uno o dos anillos de 5 o 6 miembros y 1-4 heteroátomos seleccionados entre N, O y S; Rn5 y Rn6 son cada uno independientemente H, alquilo C1-C6 no sustituido o sustituido, amino no sustituido o sustituido, C(O)R8, C(O)OR8, S(O)R8, o S(O)2R8; R8 es H, alquilo C1-C6 no sustituido o sustituido, arilo C6-C10 no sustituido o sustituido o heteroarilo no sustituido o sustituido que comprende uno o dos anillos de 5 o 6 miembros y 1-4 heteroátomos seleccionados entre N, O y S, carbociclo C3-C10 no sustituido o sustituido, o heterociclo no sustituido o sustituido que comprende uno o dos anillos de 5 o 6 miembros y 1-4 heteroátomos seleccionados entre N, O y S; R es H, hidroxilo, halógeno, nitro, ciano, alquilo C1-C6 no sustituido o sustituido, alcoxi C1-C6 no sustituido o sustituido, amino no sustituido o sustituido, arilo C6-C10 sin sustituir o sustituido, heteroarilo no sustituido o sustituido que comprende uno o dos anillos de 5 o 6 miembros y 1-4 heteroátomos seleccionados entre N, O y S, carbociclo C3-C10 no sustituido o sustituido, o heterociclo no sustituido o sustituido que comprende uno o dos anillos de 3, 4, 5, 6 o 7 miembros y 1-4 heteroátomos seleccionados entre N, O y S, o Q-T; Q es un enlace o un enlazador de alquilo C1-C6 no sustituido o sustituido; T es NRn1Rn2, C(O)Ro, S(O)Rs o S(O)2Rs; Rn1 es H, alquilo C1-C6 no sustituido o sustituido, arilo C6-C10 sin sustituir o sustituido, heteroarilo no sustituido o sustituido que comprende uno o dos anillos de 5 o 6 miembros y 1-4 heteroátomos seleccionados entre N, O y S, carbociclo C3-C10 no sustituido o sustituido, o heterociclo no sustituido o sustituido que comprende uno o dos anillos de 5 o 6 miembros y 1-4 heteroátomos seleccionados entre N, O y S; Rn2 es H, alquilo C1-C6 no sustituido o sustituido, arilo C6-C10 sin sustituir o sustituido, heteroarilo no sustituido o sustituido que comprende uno o dos anillos de 5 o 6 miembros y 1-4 heteroátomos seleccionados entre N, O y S, carbociclo C3-C10 no sustituido o sustituido, heterociclo no sustituido o sustituido que comprende uno o dos anillos de 5 o 6 miembros y 1-4 heteroátomos seleccionados entre N, O y S, C(O)R4, C(O)OR4, C(O)NR4'R4, S(O)R5, S(O)2R5, S(O)NR5'R5, o S(O)2NR5'R5, o Rn1 y Rn2, tomados junto con el átomo de nitrógeno al que están unidos, forman un anillo de 4, 5, 6 o 7 miembros que comprende opcionalmente 1-3 heteroátomos adicionales seleccionados entre N, O y S;
ES10841702T 2009-12-30 2010-12-29 Compuestos de imidazopiridinil-aminopiridina Active ES2531109T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29092309P 2009-12-30 2009-12-30
PCT/US2010/062440 WO2011082270A2 (en) 2009-12-30 2010-12-29 Substituted imidazopyridinyl-aminopyridine compounds

Publications (1)

Publication Number Publication Date
ES2531109T3 true ES2531109T3 (es) 2015-03-10

Family

ID=44227150

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10841702T Active ES2531109T3 (es) 2009-12-30 2010-12-29 Compuestos de imidazopiridinil-aminopiridina

Country Status (20)

Country Link
US (1) US8501770B2 (es)
EP (1) EP2519522B1 (es)
JP (1) JP5774602B2 (es)
KR (1) KR101689421B1 (es)
CN (1) CN102781940B (es)
AU (1) AU2010339533B2 (es)
BR (1) BR112012016398B1 (es)
CA (1) CA2785536C (es)
CO (1) CO6511271A2 (es)
DK (1) DK2519522T3 (es)
ES (1) ES2531109T3 (es)
IL (1) IL220571A (es)
MX (1) MX2012007367A (es)
MY (1) MY157124A (es)
NZ (1) NZ600801A (es)
PH (1) PH12012501323A1 (es)
RU (1) RU2619463C2 (es)
SG (1) SG181947A1 (es)
TW (1) TWI585086B (es)
WO (1) WO2011082270A2 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815854B2 (en) 2011-06-24 2014-08-26 Arqule, Inc. Substituted imidazopyridinyl compounds
KR20190015600A (ko) * 2011-06-24 2019-02-13 아르퀼 인코포레이티드 치환된 이미다조피리디닐-아미노피리딘 화합물
WO2013078254A1 (en) * 2011-11-22 2013-05-30 Array Biopharma Inc. Bicyclic heteroaryl derivatives as kinase inhibitors
AU2013262578B2 (en) * 2012-05-17 2017-07-13 The University Of Chicago Fluorinated derivatives of 4-aminopyridine
US9617215B2 (en) 2012-05-17 2017-04-11 The University Of Chicago Use of fluorinated derivatives of 4-aminopyridine in therapeutics and medical imaging
US10059663B2 (en) 2013-08-29 2018-08-28 Kyoto Pharmaceutical Industries, Ltd. Aromatic compound and use thereof
GB201321741D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
TWI662033B (zh) * 2014-03-24 2019-06-11 美商亞闊股份有限公司 製備３－（３－（４－（１－胺基環丁基）苯基）－５－苯基－３Ｈ－咪唑並［４，５－ｂ］吡啶－２－基）吡啶－２－胺之方法
ES2745156T3 (es) * 2014-04-22 2020-02-27 Arqule Inc Sales y polimorfos de un compuesto imidazopiridinil-aminopiridina sustituido
EP3189036B1 (en) * 2014-09-05 2023-07-19 ArQule, Inc. Compositions and methods for treating proliferation disorders
CN105315161B (zh) * 2015-06-05 2017-08-04 厦门医学院 一类PKB/Akt抑制剂的关键中间体的制备方法
WO2018013430A2 (en) 2016-07-12 2018-01-18 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus infection
US11208478B2 (en) 2016-08-07 2021-12-28 The Wistar Institute Of Anatomy And Biology Methods of detecting and treating a tumor expressing pT346 PDK1
EP3709986B1 (en) 2017-11-14 2023-11-01 Merck Sharp & Dohme LLC Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
CN111344287B (zh) 2017-11-14 2023-12-19 默沙东有限责任公司 作为吲哚胺2，3-双加氧酶(ido)抑制剂的新型取代的联芳基化合物
JP7640458B2 (ja) 2018-10-05 2025-03-05 アンナプルナ バイオ インコーポレイテッド Ａｐｊ受容体活性に関連する状態を処置するための化合物および組成物
US12419865B2 (en) 2018-12-06 2025-09-23 Arisan Therapeutics Inc. Compounds for the treatment of arenavirus infection
TWI904095B (zh) * 2019-07-25 2025-11-11 印度商裘拉德製藥私人有限公司 乙醯輔酶a合成酶短鏈2(acss2)之小分子抑制劑
JP7564888B2 (ja) * 2020-05-01 2024-10-09 ギリアード サイエンシーズ， インコーポレイテッド Ｃｄ７３阻害性２，４－ジオキソピリミジン化合物
CN114262322B (zh) * 2020-09-16 2026-01-06 中国科学院上海有机化学研究所 一类细胞程序性坏死抑制剂及其制备方法和用途
IL301567A (en) * 2020-09-30 2023-05-01 Chia Tai Tianqing Pharmaceutical Group Co Ltd A compound as an AKT KINASE inhibitor
CN114315839B (zh) * 2020-09-30 2025-09-26 武汉人福创新药物研发中心有限公司 嘧啶二酮类化合物及其用途
WO2022250170A1 (en) 2021-05-28 2022-12-01 Taiho Pharmaceutical Co., Ltd. Small molecule inhibitors of kras mutated proteins
EP4422756A1 (en) 2021-10-29 2024-09-04 Gilead Sciences, Inc. Cd73 compounds
EP4486390A1 (en) * 2022-03-02 2025-01-08 Terremoto Biosciences, Inc Covalent modifiers of akt1 and uses thereof
WO2024064026A1 (en) * 2022-09-19 2024-03-28 Alterome Therapeutics, Inc. Akt1 modulators
CN120225521A (zh) * 2022-09-26 2025-06-27 亚特罗姆医疗公司 Akt1调节剂
WO2024102621A1 (en) * 2022-11-09 2024-05-16 Alterome Therapeutics, Inc. Akt1 modulators
WO2024107565A1 (en) * 2022-11-14 2024-05-23 Alterome Therapeutics, Inc. Akt1 modulators
AU2024225909A1 (en) * 2023-02-24 2025-07-31 Terremoto Biosciences, Inc. Covalent modifiers of akt1 and uses thereof
WO2025059469A1 (en) * 2023-09-15 2025-03-20 Atavistik Bio, Inc. Substituted aminopyridine compounds as akt inhibitors
WO2025059577A1 (en) * 2023-09-15 2025-03-20 Atavistik Bio, Inc. Substituted aminopyridine compounds for use as akt1 inhibitors
WO2025059562A1 (en) * 2023-09-15 2025-03-20 Atavistik Bio, Inc. Substituted aminopyridine compounds and methods of treating disease using same
TW202530213A (zh) 2023-10-13 2025-08-01 美商特瑞莫托生物科學股份有限公司 Ａｋｔ１之半胱胺酸共價修飾劑及其用途
WO2025085748A1 (en) 2023-10-20 2025-04-24 Merck Sharp & Dohme Llc Small molecule inhibitors of kras proteins
WO2025128834A1 (en) * 2023-12-15 2025-06-19 Alterome Therapeutics, Inc. Akt1 modulators
WO2025188662A1 (en) * 2024-03-06 2025-09-12 Alterome Therapeutics, Inc. Akt1 modulators
WO2025188658A1 (en) * 2024-03-06 2025-09-12 Alterome Therapeutics, Inc. Akt1 modulators
WO2025207620A1 (en) * 2024-03-27 2025-10-02 Alterome Therapeutics, Inc. Akt1 modulators
TW202602874A (zh) * 2024-03-27 2026-01-16 美商亞特羅姆醫療公司 Akt1抑制劑及其鹽之固態形式
WO2025217330A1 (en) * 2024-04-10 2025-10-16 Terremoto Biosciences, Inc. Cysteine covalent modifiers of akt1 and uses thereof
WO2026035750A1 (en) * 2024-08-05 2026-02-12 Pivot Therapeutics, Inc. Inhibitors of akt and uses thereof
WO2026049331A1 (ko) * 2024-08-26 2026-03-05 이화여자대학교 산학협력단 신규한 이미다조피리딘 또는 이미다조피라진 유도체 및 이의 용도

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE3722992A1 (de) 1987-07-11 1989-01-19 Thomae Gmbh Dr K Neue imidazo-pyridine und purine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
CA2002859C (en) 1988-11-29 1998-12-29 Jean P. F. Van Wauwe Method of treating epithelial disorders
DE4129603A1 (de) 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
EP0800391A1 (en) 1994-12-28 1997-10-15 Janssen Pharmaceutica N.V. Benzimidazoles as inhibitors of calcitriol metabolism
AU3538899A (en) 1998-04-30 1999-11-23 Nippon Chemiphar Co. Ltd. Condensed imidazole derivative and therapeutic agent for liver disease
JP2000344780A (ja) 1998-09-24 2000-12-12 Fuji Photo Film Co Ltd 新規ベンゾピラン化合物、発光素子材料及びそれを使用した発光素子
US6403588B1 (en) * 2000-04-27 2002-06-11 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
WO2001083481A1 (en) * 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
GB0206861D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Medicaments
GB0206860D0 (en) * 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
PT1499316E (pt) 2002-04-18 2008-06-30 Schering Corp Derivados de (1-4-piperidinil)benzimidazole úteis como antagonistas de histamina h3
GB0215293D0 (en) * 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
AR045134A1 (es) * 2003-07-29 2005-10-19 Smithkline Beecham Plc Compuesto de 1h - imidazo [4,5-c] piridin-ilo, composicion farmaceutica que lo comprende, proceso para prepararla, su uso para preparar dicha composicion farmaceutica, combinacion farmaceutica, uso de la combinacion farmaceutica para la preparacion de un medicamento, procedimientos para preparar dic
US7442709B2 (en) * 2003-08-21 2008-10-28 Osi Pharmaceuticals, Inc. N3-substituted imidazopyridine c-Kit inhibitors
DE602004020073D1 (de) * 2003-08-21 2009-04-30 Osi Pharm Inc 3-substituierte imidazopyridinderivate als c-kit-inhibitoren
EP1960382A1 (en) 2005-11-03 2008-08-27 ChemBridge Research Laboratories, Inc. Heterocyclic compounds as tyrosine kinase modulators
US20070142369A1 (en) * 2005-12-21 2007-06-21 Margaret Van Heek Combination of an H3 antagonist/inverse agonist and an appetite suppressant
ES2336625T3 (es) * 2006-03-22 2010-04-14 Vertex Pharmaceuticals Incorporated Inhibidores de la proteina quinasa c-met para el tratamiento de trastornos proliferativos.
CN100398540C (zh) 2006-04-03 2008-07-02 大连理工大学 芳杂环基咪唑并萘酰亚胺类化合物及其应用
PT2054405E (pt) 2006-07-11 2013-12-24 Dae Woong Pharma Novos derivados de biaril benzoimidazol e composição farmacêutica que compreende os mesmos
CN101674827A (zh) 2007-03-02 2010-03-17 先灵公司 苯并咪唑衍生物及其使用方法
WO2009000413A1 (en) 2007-06-26 2008-12-31 Sanofi-Aventis A regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles
CN101802129B (zh) 2007-10-17 2014-01-01 第一毛织株式会社 有机光电装置用新化合物及包括该化合物的有机光电装置
KR20090007347U (ko) 2008-01-16 2009-07-21 춘-치 왕 가속 페달 포지션 센서를 구비한 자동차용 연료 공급 기구

Also Published As

Publication number Publication date
CA2785536A1 (en) 2011-07-07
US8501770B2 (en) 2013-08-06
PH12012501323A1 (en) 2014-12-17
KR101689421B1 (ko) 2016-12-23
KR20120120271A (ko) 2012-11-01
BR112012016398A2 (pt) 2018-08-21
RU2619463C2 (ru) 2017-05-16
BR112012016398B1 (pt) 2021-12-21
AU2010339533A1 (en) 2012-07-12
EP2519522A4 (en) 2013-03-13
HK1177458A1 (en) 2013-08-23
TWI585086B (zh) 2017-06-01
MX2012007367A (es) 2013-04-03
SG181947A1 (en) 2012-07-30
IL220571A (en) 2015-03-31
DK2519522T3 (en) 2014-12-08
EP2519522A2 (en) 2012-11-07
NZ600801A (en) 2013-09-27
EP2519522B1 (en) 2014-09-24
CN102781940A (zh) 2012-11-14
US20110172203A1 (en) 2011-07-14
JP2013516419A (ja) 2013-05-13
RU2012132444A (ru) 2014-02-10
WO2011082270A3 (en) 2011-11-17
CA2785536C (en) 2018-02-27
CN102781940B (zh) 2016-09-07
AU2010339533B2 (en) 2015-05-07
JP5774602B2 (ja) 2015-09-09
MY157124A (en) 2016-05-13
TW201132640A (en) 2011-10-01
WO2011082270A2 (en) 2011-07-07
CO6511271A2 (es) 2012-08-31

Similar Documents

Publication Publication Date Title
ES2531109T3 (es) Compuestos de imidazopiridinil-aminopiridina
ES2515194T3 (es) Derivados de pirrolidina
ES2530943T3 (es) Derivados de la cromenona con actividad antitumoral
AR076170A1 (es) Derivados heterociclicos imidazolicos y/o oxazolicos utiles como agentes antivirales para hepatitis c y composiciones farmaceuticas que los comprenden.
AR078163A1 (es) Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes
AR057626A1 (es) Derivados de pirido pirazo y pirimido- pirimidina y su uso como inhibidores de mtor
AR090398A1 (es) Inhibidores heterociclicos de glutaminasa
AR082029A1 (es) Derivados de heterociclos nitrogenados, composiciones y metodos para modular la via de señalizacion de wnt
CO6150164A2 (es) Derivados de 2-metilmorfolina pirido-,pirazo-ypirimido-pirimidina como inhibidores de mtor
PE20141202A1 (es) Compuesto de ciclopropanoamina
PE20140863A1 (es) Compuestos de benceno sustituidos con arilo o heteroarilo
AR094312A1 (es) Inhibidores del receptor del factor de crecimiento de fibroblastos
AR086181A2 (es) Metodo para preparar inhibidores macrociclicos inhibidores de serina proteasas del virus de la hepatitis c
AR077990A1 (es) Compuestos heterociclicos como inhibidores de janus quinasa
AR081573A1 (es) N-[(het)ariletil)]pirazo(tio)carboxamidas y sus analogos heterosustituidos y su uso como fungicidas
AR040351A1 (es) Derivados de quinuclidina-amida, composicion farmaceutica, procedimiento de preparacion del compuesto y su uso para fabricar medicamentos
AR088829A1 (es) DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3
AR082889A1 (es) Compuestos y composiciones para la inhibicion de nampt
AR062110A1 (es) Derivado de anillo fusionado de espiroquetas y su uso como farmaco antidiabetico
AR082441A1 (es) Uso de ligandos sigma en la hiperalgesia inducida por opioides
AR065927A1 (es) Derivados de 5,6-dihidro-1h-piridin-2-ona
UY31014A1 (es) Derivados de ftalazinona
AR084730A1 (es) Ligandos heterociclicos nitrogenados de receptores sigma utiles para el tratamiento de dolor por cancer de huesos
AR086636A1 (es) Ligandos sigma utiles para tratar y/o prevenir el dolor asociado a la diabetes tipo 2 y composiciones farmaceuticas que los contienen
CO6410301A2 (es) 1 aril -3- aminoalcoxi-pirazoles como ligandos sigma para potenciar ell efecto analgesico de los opioides y atenuar la dependencia de ellos